GlassScriptPhysician profile
Sleman A Khoury
NPI 1578543849
$63,225.31
in general payments reported to CMS, 2019-2025
67 companies · $6,357 in 2025
The $6,357 reported for 2025 was more than what 88% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $5,034 · 2021: $3,538 · 2022: $3,713 · 2023: $3,640 · 2024: $3,746 · 2025: $6,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,989 · Travel and Lodging: $39.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,713.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,989.00 |
| Travel and Lodging | $39.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $17,905.49 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $12,237.63 | 2019-2022 | |
| Novo Nordisk INC | $9,417.62 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $3,180.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Ascendis Pharma Endocrinology INC | $2,539.15 | 2022-2025 | Yorvipath |
| Amgen INC. | $1,812.14 | 2019-2025 | Tepezza, Evenity, Prolia |
| Corcept Therapeutics | $1,544.85 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,507.13 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,162.38 | 2019-2023 | Farxiga |
| Tandem Diabetes Care, INC. | $984.05 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $903.36 | 2021-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $847.32 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $664.78 | 2021-2025 | |
| Abbott Laboratories | $660.84 | 2019-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $619.09 | 2019-2025 | Xyosted, Nocdurna, Tlando |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sleman Khoury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.